Latest Tardive dyskinesia Stories
TITUSVILLE, N.J., Dec. 10 /PRNewswire/ -- Treatment with once-monthly INVEGAÂ® SUSTENNA(TM) is not inferior to treatment with bi-weekly RISPERDALÂ® CONSTAÂ®, according to new data from a comparative study of both treatments in patients with schizophrenia.
WILMINGTON, N.C., Sept. 9 /PRNewswire/ -- Wilmington Pharmaceuticals announced today the U.S.
Schering-Plough Corp.'s asenapine has been cleared for sale as a treatment for schizophrenia and bipolar disorder in adults, U.S.
Schering-Plough Corporation (NYSE: SGP) today announced that the U.S. Food and Drug Administration (FDA) has approved SAPHRIS(R) (asenapine) sublingual tablets for acute treatment of schizophrenia in adults and acute treatment of manic or mixed episodes associated with bipolar I disorder with or without psychotic features in adults.
The US Food and Drug Administration is requiring makers of the heartburn drug Reglan to add a â€œblack boxâ€ warning to inform patients that long term or high doses of the drug have been linked to involuntary movement throughout the body.
DURHAM, N.C., Jan. 13 /PRNewswire/ -- S&R Communications Group has entered a strategic partnership with Ovation Pharmaceuticals, Inc., to launch Xenazine* (tetrabenazine), a treatment for chorea associated with Huntington's disease (HD).
INDIANAPOLIS, Jan. 7 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) announced today that it received a complete response letter from the U.S.
By Rita Rubin Baylor College of Medicine neurologist Joseph Jankovic is a patient man. With the Food and Drug Administration's OK, Jankovic has studied the drug tetrabenazine since 1979.
- The act of burning, scorching, or heating to dryness; the state or being thus heated or dried.
- In medicine, cauterization.